近日,总部位于中国的生物制药上市公司康方生物与 总部位于美国加利福尼亚的生物制药上市公司Summit Therapeutics Inc. 签署了一项交易总金额有望高达50亿美元合作许可协议。盛德律师事务所为康方生物提供了全程的法律服务。
据悉,康方生物将授权其突破性双特异性抗体ivonescimab在美国、加拿大、欧洲及日本市场的开发及商业化。
本次合作,康方生物将获得5亿美元预付款,潜在交易总价值还包括开发、注册和商业化里程碑款项付款可高达45亿美元。康方生物还将获得销售净额的低双位比例的提成作为ivonescimab 的特许专利使用费。
盛德团队由合伙人律师陆海波、Stephen Abreu、 Asher Rubin及主办律师王龙波率领。
Sidley Austin Represents Akeso in US$5 Billion Licensing Agreement With Summit Therapeutics
Sidley Austin is representing China based BioTech company Akeso Inc. in a high-profile US$5 billion collaboration and licensing agreement with the U.S. based BioTech company Summit Therapeutics Inc. to out-license its breakthrough bispecific antibody, ivonescimab, for development and commercialization in the U.S., Canada, Europe, and Japan.
Under the terms of the agreement, Akeso will receive a US$500 million upfront payment, with a total potential deal value of up to US$5 billion. Akeso will also receive a low double-digit percentage of royalties on net product sales of ivonescimab.
The Sidley team is led by partner James Lu, Stephen Abreu, Asher Rubin, and Wang Longbo.
TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM